{"id":"valium-akineton-dehydrobenzperidol-atropine-sulfate","safety":{"commonSideEffects":[{"rate":null,"effect":"Sedation/drowsiness"},{"rate":null,"effect":"Anticholinergic effects (dry mouth, urinary retention, constipation)"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Extrapyramidal side effects"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":{"chemblId":"CHEMBL1396281","moleculeType":"Small molecule","molecularWeight":"387.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Valium (diazepam) is a benzodiazepine that enhances GABA inhibitory neurotransmission; Akineton (biperiden) is an anticholinergic agent that blocks muscarinic receptors; Dehydrobenzperidol is a butyrophenone antipsychotic blocking dopamine D2 receptors; and Atropine sulfate is an anticholinergic that further blocks muscarinic acetylcholine receptors. Together, these agents produce profound CNS depression, antipsychotic activity, and anticholinergic effects.","oneSentence":"This combination drug produces sedation, muscle relaxation, and antipsychotic effects through multiple central nervous system depressants and anticholinergic agents acting simultaneously.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:42:07.714Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute agitation and psychotic episodes (historical use)"},{"name":"Sedation in psychiatric settings (historical use)"}]},"trialDetails":[{"nctId":"NCT02078336","phase":"PHASE4","title":"Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2013-12","conditions":"Dental Care for Disabled","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Valium + Akineton + Dehydrobenzperidol + Atropine sulfate","genericName":"Valium + Akineton + Dehydrobenzperidol + Atropine sulfate","companyName":"Universitaire Ziekenhuizen KU Leuven","companyId":"universitaire-ziekenhuizen-ku-leuven","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug produces sedation, muscle relaxation, and antipsychotic effects through multiple central nervous system depressants and anticholinergic agents acting simultaneously. Used for Acute agitation and psychotic episodes (historical use), Sedation in psychiatric settings (historical use).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}